Orexo
Orexo AB, a leading pharmaceutical company headquartered in Sweden, focuses on developing innovative treatments for addiction and pain management. Founded in 1995, Orexo has established a strong presence in Europe and North America, with a commitment to addressing unmet medical needs through advanced drug delivery technologies. The company’s core products, including Zubsolv, a sublingual film for opioid dependence, exemplify its unique approach to patient care. Orexo's dedication to research and development has positioned it as a key player in the pharmaceutical industry, with notable achievements in improving treatment outcomes for patients struggling with addiction. With a robust pipeline and a focus on sustainable growth, Orexo continues to make significant strides in enhancing the quality of life for individuals facing complex health challenges.
DitchCarbon Score
How does Orexo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orexo's score of 48 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Orexo's reported carbon emissions
In 2024, Orexo reported total carbon emissions of approximately 1,537,000 kg CO2e, a decrease from about 2,006,000 kg CO2e in 2023. The emissions breakdown for 2024 includes Scope 1 emissions of about 312,000 kg CO2e, Scope 2 emissions of approximately 366,000 kg CO2e, and Scope 3 emissions of about 859,000 kg CO2e. This reflects a continued commitment to reducing their carbon footprint, particularly in Scope 1 and 2 emissions, which saw a 3% reduction in 2023 compared to the 2022 baseline, primarily due to lower emissions from sales travel. The company has not set specific Science-Based Targets Initiative (SBTi) targets but has demonstrated a proactive approach to emissions reduction through documented initiatives. The emissions data is sourced directly from Orexo AB (publ) and is not cascaded from any parent organization. Overall, Orexo's climate commitments are evident in their ongoing efforts to monitor and reduce emissions across all scopes, aligning with industry standards for sustainability and climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 284,000 | 000,000 | 000,000 |
| Scope 2 | 405,000 | 000,000 | 000,000 |
| Scope 3 | 1,573,000 | 0,000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orexo is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
